| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
As a chemical intermediate, N-Formylglycine ethyl ester does not have a defined biological target. Some studies explore the potential antiviral properties of the compound, suggesting it may inhibit the replication of certain RNA viruses. However, more investigation is needed to understand the mechanisms and effectiveness of this antiviral activity. Although specific biological activity data for N-Formylglycine ethyl ester is limited, compounds with similar structures often exhibit biological properties. N-formyl amino acids are known to play roles in peptide synthesis and can influence biological pathways involving protein synthesis and enzyme function. The formyl group may also affect the compound's interaction with biological receptors, potentially impacting its pharmacological profile. The compound's primary role is as a synthetic building block rather than a pharmacologically active agent.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of N-Formylglycine ethyl ester is evaluated through its performance in organic synthesis reactions. It serves as a building block for synthesizing peptides and other bioactive molecules. As a formylating agent, it introduces a formyl group (HCO) into other molecules. The compound is used in the preparation of ethyl isocyanoacetate, a key intermediate in the synthesis of various heterocyclic compounds. Its reactivity is characterized by its ability to participate in acylation and condensation reactions. The compound's specific formylation at the nitrogen atom significantly alters its reactivity compared to other amino acid derivatives. No inherent biological activity is typically observed as the compound is primarily a synthetic intermediate. |
| ln Vivo |
In vivo activity is not applicable for N-Formylglycine ethyl ester. The compound is not intended for administration to living organisms. It is exclusively a research chemical for laboratory synthesis.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for N-Formylglycine ethyl ester involves standard organic synthesis procedures. A typical workflow: dissolve in ethyl acetate, add base (e.g., TEA), and couple with acid chlorides or activated esters. Monitor by TLC. Purify by distillation or column chromatography. Characterize by NMR (formyl proton at ~8 ppm). The compound is used as an intermediate in the preparation of aminomethylene compounds and pyridine derivatives. It is soluble in common organic solvents. The compound has an XLogP3 value of -0.2, indicating relatively low lipophilicity.
|
| Cell Assay |
In vitro cell-based experimental workflows are not typically performed with N-Formylglycine ethyl ester. The compound is not intended for biological activity screening. Any cell-based studies would involve the final products synthesized from this intermediate rather than the compound itself.
|
| Animal Protocol |
In vivo animal experiments are not applicable for N-Formylglycine ethyl ester. The compound is stored at room temperature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N-Formylglycine ethyl ester have not been characterized. The compound is not a drug. No ADME data are available.
|
| Toxicity/Toxicokinetics |
The toxicological data for N-Formylglycine ethyl ester indicate it is a flammable liquid and vapor (H226). The compound may cause skin and eye irritation. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
N-Formylglycine ethyl ester is a unique compound due to its specific formylation at the nitrogen atom, which significantly alters its reactivity compared to other amino acid derivatives. This structural modification allows for diverse applications in organic synthesis and biochemistry that may not be achievable with simpler compounds like glycine ethyl ester. The compound finds applications in peptide synthesis as a building block, organic synthesis as an intermediate, and research related to amino acid derivatives and their properties. It is not a drug and has no clinical trials or approvals. The compound is for research use only. The GHS information indicates H226 (100%): Flammable liquid and vapor. The compound has a flash point of 112°F and a boiling point of 150-151°C. It is stable but incompatible with strong oxidizing agents.
|
| Molecular Formula |
C5H9NO3
|
|---|---|
| Molecular Weight |
131.13
|
| Exact Mass |
131.058
|
| CAS # |
3154-51-6
|
| PubChem CID |
76615
|
| Appearance |
Colorless to light yellow liquid（Density：1.15 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
278.4±23.0 °C at 760 mmHg
|
| Flash Point |
122.2±22.6 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.424
|
| LogP |
0.03
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
102
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)CNC=O
|
| InChi Key |
GMBCCEOJUWMBPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H9NO3/c1-2-9-5(8)3-6-4-7/h4H,2-3H2,1H3,(H,6,7)
|
| Chemical Name |
ethyl 2-formamidoacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6260 mL | 38.1301 mL | 76.2602 mL | |
| 5 mM | 1.5252 mL | 7.6260 mL | 15.2520 mL | |
| 10 mM | 0.7626 mL | 3.8130 mL | 7.6260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
